Insights - Bellus announced a $35M CDN raise this morning at $0.95 CDN. That is roughly equivalent to $0.71 USD. The Company is expected to net around $33M CDN, … Continue Reading
Read nowInsights - There is a misconception that Bellus is lacking catalysts following their strong Phase 1 data released last week (read here). We don’t necessarily agree with the … Continue Reading
Read nowInsights - Bellus had a call this morning (listen here) to discuss their Phase 1 data, released yesterday after market. As reported yesterday, at their anticipated therapeutic doses … Continue Reading
Read nowInsights - Bellus is expected to report Phase 1 data, which will include taste, sometime in late November – early December. Below we analyze Merck’s Phase 2b … Continue Reading
Read nowInsights - Menlo (MNLO), a company developing serlopitant for chronic cough candidate, reported disappointing Phase 2 data. In 185 patients, serlopitant group had 31% less reduction than the placebo group. In … Continue Reading
Read nowInsights - In December, Bellus Health (BLUSF:OTC) (BLU:TSX) will report Phase 1 data for their chronic cough candidate BLU-5937. Bellus’ candidate is a P2X3 inhibitor, a class … Continue Reading
Read nowDigital Conferences - TRANSCRIPT OF EVENT Deniel Mero Welcome to PropThink’s First-Ever Digital Conference. My name is Deniel Mero, Editor of PropThink. I will be hosting today’s event. … Continue Reading
Read now
